This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


ELIQUIS® (apixaban) Half-Life & Excretion

  • ELIQUIS has multiple routes of elimination1
  • Of the administered dose in humans,
    approximately 25% was recovered as metabolites,
    with the majority recovered in faeces1
  • Additional contributions from biliary and direct
    intestinal excretion were observed in clinical and
    non-clinical studies, respectively1
  • Renal excretion of ELIQUIS accounts for
    approximately 27% of total clearance1
  • ELIQUIS has a half-life of approximately 12 hours1

REFERENCE

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.